Santen Publishes its Annual Integrated Report “Santen Report 2025”
September 25, 2025 - Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter Santen) today announced the release of the “Santen Report 2025” (Integrated Report for the fiscal year ended March 31, 2025). Available in both English and Japanese, the report is a comprehensive source of financial and non-financial information. The report can be accessed on Santen’s investor relations (IR) website. https://www.santen.com/en/ir/document/annual
Since its establishment in Japan in 1890, and guided by its Core Principle, “Tenki ni sanyo suru,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. In addition to introducing Santen’s new Corporate Philosophy Framework, this edition of the report describes its medium- to long-term strategies and initiatives for sustainable growth, and the management foundation underpinning execution of these strategies, from both financial and non-financial perspectives while explaining how Santen intends to create further value for patients and society. Santen will continue to communicate with its stakeholders as it strives, under the organizational capability of “Santen Commercial Excellence*1,” to become a leading ophthalmology company, earning the trust of patients and the global ophthalmic community while aspiring to realize “Happiness with Vision” by providing products and services that are of value to patients, consumers, and medical professionals worldwide.
Overview of Santen Report 2025:
Introduction: Santen’s Values
- This section introduces Santen’s new Corporate Philosophy Framework, updated in February 2025, and Santen’s value creation process for contributing to the sustainable development of society while seeking to be a leading ophthalmology company that earns the trust of patients and ophthalmic communities around the world.
Strategies and Initiatives for Sustainable Value Creation and Growth
- Santen announced its new FY2025-2029 Medium-Term Management Plan this past May. In the message from President and CEO Takeshi Ito, the report looks back on the previous Medium-Term Management Plan covering FY2023-2025 and describes the thoughts and background behind the development of the new Medium-Term Management Plan. This new plan embodies the company’s continued pursuit of “what only Santen can achieve” as it strives for further growth.
- Following the CEO's Message are details of the FY2025-2029 Medium-Term Management Plan. This section explains what Santen aspires to be in 2035, the growth strategy centered on Santen's business model, as well as consolidated numerical targets. Also introduced are the materialities that were reviewed during the development of the Medium-Term Management Plan.
- Chief Financial Officer Kazuo Koshiji provides a financial review of the previous Medium-Term Management plan (FY2023-2025) and explains the financial strategy that will support execution of the FY2025-2029 Medium-Term Management Plan.
- Chief Operating Officer Rie Nakajima introduces the future development of Santen Commercial Excellence, the foundation for Santen’s business model, and outlines strategies for each region.
- The report also introduces initiatives for creating new markets in the areas of myopia and ptosis and for strengthening the Rx*² portfolio and pipeline to support medium- to long-term growth. Also provided is an overview of the new Corporate Philosophy Framework - updated in February 2025 to clarify the basis for employees’ actions and decision-making - that describes the reasons for the update, the underlying principles, and specific initiatives for putting the Core Principle into practice. Initiatives related to human capital strategy and conservation of the global environment are also introduced.
The Foundation Supporting Value Creation
- This section explains Santen’s basic approach and current efforts regarding the governance system, which is essential for realizing sustainable value creation for Santen and society. In addition to reporting on the roles and activities of the Board of Directors and various committees, it also introduces messages from a newly appointed director.
*1 Santen Commercial Excellence: Organizational capabilities for leveraging synergies among Santen’s strengths in originating products and maximizing product value to effectively drive results
*2 Rx: Prescription-only medicine
About Santen
As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “Tenki ni sanyo suru,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”
For more information, please visit Santen’s website https://www.santen.com/en.
Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com
Official SNS
